{"filings":[{"id":482236,"accession_number":"0001493152-26-024061","cik":1812360,"company_name":"FOXO TECHNOLOGIES INC.","ticker":"FOXO","form_type":"8-K","filed_at":"2026-05-18T11:30:35+00:00","items":["1.01","9.01"],"status":"ready","headline":"FOXO exchanges all Series A Preferred for $7.78M in non-convertible notes, eliminating conversion rights","event_type":"debt","confidence":"high","bullets":["Exchanged 2,467.988 shares of Series A Preferred ($2.47M stated value) from Investor 1 for a senior unsecured note.","Exchanged 5,307.097 shares of Series A Preferred ($5.31M stated value) from Investor 2 for a senior unsecured note.","Total exchange value $7,775,085.28; notes mature May 12, 2027, non-interest bearing (18% default rate).","Institutional investors no longer hold any convertible instruments, removing potential equity dilution.","Proceeds from notes to be used for working capital; no interest expense unless default occurs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95680,"accession_number":"0001493152-26-018141","cik":1812360,"company_name":"FOXO TECHNOLOGIES INC.","ticker":"FOXO","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"FOXO Technologies increases authorized shares to 25.02B, effective May 3, 2026","event_type":"other_material","confidence":"high","bullets":["Authorized shares raised to 25.02B: 25B Class A common ($0.0001 par) and 20M preferred ($0.0001 par).","Amendment signed April 15, 2026; filed with Delaware Secretary of State effective May 3, 2026.","Stockholder approval obtained under DGCL Sections 212 and 242.","Prior authorized share count not disclosed; increase represents massive potential dilution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95679,"accession_number":"0001493152-26-014841","cik":1812360,"company_name":"FOXO TECHNOLOGIES INC.","ticker":"FOXO","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"FOXO Technologies majority stockholder approves authorized share increase from 10B to 25B","event_type":"other_material","confidence":"high","bullets":["Majority stockholder (Rennova Health, Inc., controlled by CEO) holding 97.59% voting rights approved via written consent on March 27, 2026.","Amendment increases authorized Class A Common Stock from 10,000,000,000 to 25,000,000,000 shares.","Effective date will be 20 days after mailing of definitive Information Statement; preliminary 14C filed April 1, 2026.","Board has discretion to set effective date without further stockholder approval.","Record date for consent was March 20, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108910,"accession_number":"0001493152-26-012423","cik":1812360,"company_name":"FOXO TECHNOLOGIES INC.","ticker":"FOXO","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CFO Sylwia Nowak Hauman resigns citing internal control concerns; FOXO appoints Celene Grant as new CFO","event_type":"leadership","confidence":"high","bullets":["Sylwia Nowak Hauman resigned as CFO on March 18, 2026; resignation letter cited concerns over internal controls, financial reporting, and team resourcing.","Company disagrees with Hauman's characterizations, says controls and staffing have improved under current management.","Celene Laurene Rattray Grant, CPA with 15+ years experience, appointed CFO on March 24, 2026.","Grant previously served as consultant Financial Controller for FOXO predecessor (2018-2021) and returned as consultant in 2024 to help restore SEC reporting compliance.","New CFO receives $200,000 annual base salary and is eligible for discretionary bonus up to $25,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108909,"accession_number":"0001493152-26-005622","cik":1812360,"company_name":"FOXO TECHNOLOGIES INC.","ticker":"FOXO","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"FOXO settles $200K debt by issuing 8,000 Series E Preferred shares to Rennova in related-party deal","event_type":"other_material","confidence":"high","bullets":["Issued 8,000 Series E Preferred shares at $25 stated value to Rennova in full satisfaction of $200,000 in Prior Advances.","Advances made Dec 4-10, 2025; exchange effective Dec 31, 2025, with closing on Feb 6, 2026.","Related-party transaction: CEO Seamus Lagan controls both FOXO and Rennova; disinterested directors approved.","Shares issued under Section 4(a)(2) exemption; no registration rights granted; not freely resalable.","Debt extinguished; no interest accrued; strengthens balance sheet but raises governance concerns."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108908,"accession_number":"0001493152-26-002919","cik":1812360,"company_name":"FOXO TECHNOLOGIES INC.","ticker":"FOXO","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"FOXO Tech increases authorized common shares from 2.5B to 10B; hospital adds tele-specialty","event_type":"other_material","confidence":"high","bullets":["Authorized shares of common stock increased to 10B from 2.5B, effective Jan 18, 2026.","Big South Fork Medical Center now offers inpatient tele-specialty in cardiology, pulmonology, nephrology via Rural Physicians Group.","Hospital implemented on-site echocardiography services with CompuMed for professional interpretation.","Management expects expanded services to reduce patient transfers and increase net revenues."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125372,"accession_number":"0001493152-25-028605","cik":1812360,"company_name":"FOXO TECHNOLOGIES INC.","ticker":"FOXO","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"FOXO Technologies amends preferred stock terms and increases authorized shares via majority stockholder consent","event_type":"other_material","confidence":"high","bullets":["Filed amendments to Series B and C Preferred Stock, revising conversion price to higher of $0.0001 or 90% of 5-day VWAP and removing mandatory conversion.","Majority stockholder Rennova Health (controlled by CEO) holding ~98.6% voting rights approved increase of Common Stock from 2.5B to 10B shares and Preferred from 10M to 20M shares.","Re-elected directors Seamus Lagan, Trevor Langley, Francis Colt deWolf III, Bret Barnes, and Mark White to board.","Ratified appointment of Kreit & Chiu CPA LLP as independent auditor for fiscal year 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125371,"accession_number":"0001493152-25-027961","cik":1812360,"company_name":"FOXO TECHNOLOGIES INC.","ticker":"FOXO","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FOXO CEO year-end review: revenue >$15M expected, Myrtle occupancy 93%, debt reduced","event_type":"other_material","confidence":"high","bullets":["Myrtle Recovery Centers avg daily census 28 (93% occupancy) vs 7.4 (25%) in 2024; projected 550 admissions vs 195.","Net revenues approx $12M for 9 months ended Sep 30, 2025; expects >$15M for full year 2025.","Equity increased from $5.3M (Dec 2024) to $20.2M (Sep 2025); debt reduced from $10.2M to $7.1M.","Acquired Vector BioSource; expects ~$1M net revenues in 2025; formed FOXO Acquisition Corp for future deals.","Common stock lost NYSE American listing in Q3 2025 due to share price; evaluating uplisting options for 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125370,"accession_number":"0001493152-25-027064","cik":1812360,"company_name":"FOXO TECHNOLOGIES INC.","ticker":"FOXO","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FOXO subsidiary Myrtle Recovery Centers recognized by Tennessee rural health association","event_type":"other","confidence":"high","bullets":["Myrtle Recovery Centers received recognition from Rural Health Association of Tennessee at annual awards luncheon on Dec 9, 2025.","Subsidiary has been operating at capacity for most of 2025, serving patients from 63 of Tennessee's 95 counties.","CEO Robert Merritt spoke at conference on substance use disorder treatment.","FOXO CEO Seamus Lagan stated recognition affirms Myrtle's role and supports growth strategy to replicate model in Tennessee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125369,"accession_number":"0001493152-25-020766","cik":1812360,"company_name":"FOXO TECHNOLOGIES INC.","ticker":"FOXO","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"FOXO Technologies amends Series D conversion price and Series E dividend frequency","event_type":"other_material","confidence":"high","bullets":["Series D conversion price changed to the higher of $0.0001 or 90% of 5-day VWAP prior to conversion notice.","Series E dividends clarified as payable semi-annually, not quarterly, per amended certificate.","Amended and Restated Certificates of Designation filed with Delaware Secretary of State on October 29, 2025.","No other material changes to rights, privileges, or preferences of the preferred stock series."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125368,"accession_number":"0001493152-25-019077","cik":1812360,"company_name":"FOXO TECHNOLOGIES INC.","ticker":"FOXO","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"FOXO Technologies increases authorized common shares from 500M to 2.5B","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 500,000,000 to 2,500,000,000 effective Oct 22, 2025.","Stockholder approval previously obtained; Certificate of Amendment filed with Delaware.","No immediate dilution; shares available for future financing or other corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142095,"accession_number":"0001493152-25-015704","cik":1812360,"company_name":"FOXO TECHNOLOGIES INC.","ticker":"FOXO","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"FOXO appoints Sylwia Nowak Hauman as CFO, amends Series A Preferred terms","event_type":"leadership","confidence":"high","bullets":["Sylwia Nowak Hauman appointed CFO (Principal Financial & Accounting Officer) effective September 23, 2025.","Hauman brings 25+ years finance experience, most recently VP Finance at Payall Payment Systems.","Annual salary of $200,000 with possible $25,000 bonus approved by board.","Amended certificate increases Series A Preferred authorized shares to 50,000, revises voting and conversion price.","Conversion price set at higher of $0.0001 or 90% of 5-day VWAP prior to conversion notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142094,"accession_number":"0001493152-25-014507","cik":1812360,"company_name":"FOXO TECHNOLOGIES INC.","ticker":"FOXO","form_type":"8-K","filed_at":"2025-09-22T23:59:59+00:00","items":["2.01","3.02","7.01","9.01"],"status":"ready","headline":"FOXO closes acquisition of Vector Bio Source; $500K cash, preferred stock, and warrants","event_type":"m_and_a","confidence":"high","bullets":["On Sept 19, 2025, FOXO completed the purchase of Vector Bio Source, which became a wholly owned subsidiary.","Total consideration: $500,000 cash, 60,000 Series E Cumulative Redeemable Secured Preferred Shares, and warrants for up to $2M of common stock.","Warrants have an exercise price of $0.00517 per share and a 9.99% beneficial ownership limitation.","Shares and warrants were issued in a private placement exempt from registration under Section 4(a)(2) and Rule 506(b)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142093,"accession_number":"0001493152-25-013731","cik":1812360,"company_name":"FOXO TECHNOLOGIES INC.","ticker":"FOXO","form_type":"8-K","filed_at":"2025-09-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Majority stockholder approves 5x increase in authorized Class A common shares to 2.5B","event_type":"other_material","confidence":"high","bullets":["Majority stockholder (Rennova Health, controlled by CEO) holding 56.71% of voting rights approved share authorization increase.","Authorized Class A Common Stock to rise from 500M to 2.5B shares, effective by March 31, 2026 at Board's discretion.","The increase requires no further stockholder approval; definitive Information Statement to be mailed, effective 20 days after mailing.","CEO Seamus Lagan controls the majority stockholder, giving him effective control over the authorization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142092,"accession_number":"0001493152-25-013552","cik":1812360,"company_name":"FOXO TECHNOLOGIES INC.","ticker":"FOXO","form_type":"8-K","filed_at":"2025-09-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"FOXO acquires Vector BioSource for $500K cash, Series E shares, and warrants","event_type":"m_and_a","confidence":"high","bullets":["Purchase price includes $500K cash, 60,000 Series E Preferred shares, and warrants for up to $2M common stock at 110% of pre-close price.","Contingent earnout of up to 80,000 Series E shares if Vector achieves $4M qualifying revenue in year 2 after closing.","Closing requires due diligence, final warrants/employment agreements, and 12-month budget with up to $1.2M funding.","Sellers have limited right to repurchase shares at fair market value with a floor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142091,"accession_number":"0001493152-25-013398","cik":1812360,"company_name":"FOXO TECHNOLOGIES INC.","ticker":"FOXO","form_type":"8-K","filed_at":"2025-09-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FOXO Technologies signs agreement to acquire Vector Biosource Inc.","event_type":"m_and_a","confidence":"high","bullets":["Purchase price: $500K cash, 60K Series E Preferred ($1.5M stated value), warrants for $2M common stock at 10% premium to closing price.","Up to additional 80K Series E Preferred shares ($2M stated value) contingent on future revenue and cash collection milestones.","FOXO to fund up to $1.2M for Vector's growth initiatives; Vector had Q2 2025 net revenue of ~$225K ($0.9M annualized).","Closing subject to due diligence, finalization of warrant and employment agreements; expected as soon as practical.","Vector provides data and biospecimen sourcing for biotech, clinical research, and pharma industries."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142090,"accession_number":"0001641172-25-026881","cik":1812360,"company_name":"FOXO TECHNOLOGIES INC.","ticker":"FOXO","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FOXO Technologies amends Smithline settlement, pays $97,837 in cash","event_type":"other_material","confidence":"high","bullets":["Amendment No. 1 to Settlement Agreement dated Sept 4, 2025; remaining balance of $97,837 to be paid in cash.","Payments: $25,000 immediate, $25,000 by Sept 27, 2025, $25,000 by Oct 27, 2025, final $22,837 by Nov 27, 2025.","Original Nov 2023 settlement was $2.3 million converted to Class A Common Stock; this cash payment satisfies remaining balance in full.","Cash payment replaces issuance of shares; avoids dilution for FOXO shareholders.","Settlement with Smithline Family Trust II is fully resolved as of Nov 27, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142089,"accession_number":"0001641172-25-026820","cik":1812360,"company_name":"FOXO TECHNOLOGIES INC.","ticker":"FOXO","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Majority stockholder approves reverse stock split of FOXO common stock at ratio up to 1:500","event_type":"other_material","confidence":"high","bullets":["Rennova Health (controlled by CEO) holds 60% voting rights, approved reverse split via written consent on Sept 2, 2025.","Reverse split ratio from 1:10 to 1:500; Board will set exact ratio, must act by July 31, 2026.","Company to file preliminary Schedule 14C; reverse split effective 20 days after mailing definitive statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142088,"accession_number":"0001641172-25-024660","cik":1812360,"company_name":"FOXO TECHNOLOGIES INC.","ticker":"FOXO","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["3.01","4.02"],"status":"ready","headline":"FOXO delisted from NYSE American; board restates Q1 2025 financials for $5.1M error","event_type":"other_material","confidence":"high","bullets":["NYSE American commenced delisting on Aug 12, 2025 due to stock price below $0.10; trading suspended immediately.","Company transferred to OTC market; trading under symbol FOXO began Aug 13, 2025.","Board concluded Q1 2025 financials should no longer be relied upon due to error in accounting for RCHI acquisition price consideration.","Correction requires recording additional $5.1M liability and goodwill as of March 31, 2025, increasing total assets and liabilities.","No impact on income statement or cash flows; Company plans to file amended 10-Q."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142087,"accession_number":"0001641172-25-023520","cik":1812360,"company_name":"FOXO TECHNOLOGIES INC.","ticker":"FOXO","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FOXO Technologies receives NYSE American delisting notice, moves to OTC market","event_type":"other_material","confidence":"high","bullets":["NYSE Regulation commenced delisting proceedings on Aug 12, 2025 due to low selling price below $0.10.","Trading on NYSE American was suspended immediately; common stock began trading on OTC market Aug 13, 2025 under ticker FOXO.","CEO Seamus Lagan stated delisting does not change business strategy or economic outlook; company will consider relisting options.","Company remains focused on acquisitions and will file Form 10-Q for June 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142086,"accession_number":"0001641172-25-022403","cik":1812360,"company_name":"FOXO TECHNOLOGIES INC.","ticker":"FOXO","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FOXO Technologies executes non-binding agreement to acquire assisted living facility in South Florida for $22M","event_type":"m_and_a","confidence":"medium","bullets":["Facility has 87 units licensed for assisted living and memory care services.","Purchase price of $22M, with $5M in non-convertible preferred stock.","Completion subject to definitive agreements, due diligence, and financing.","Company expects to close on acquisitions adding over 350 units in assisted living and memory care.","Also expects to confirm definitive agreement for previously announced Vector Biosource acquisition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142085,"accession_number":"0001641172-25-021759","cik":1812360,"company_name":"FOXO TECHNOLOGIES INC.","ticker":"FOXO","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FOXO subsidiary Myrtle Recovery renews Oneida, TN license; facility at full capacity","event_type":"regulatory","confidence":"high","bullets":["License renewed by Tennessee DMHSAS after successful annual inspection for alcohol/drug residential treatment.","Oneida location at full capacity with a waiting list, per Myrtle CEO Robert Merritt.","CEO Seamus Lagan says company considering expansion and possible acquisitions for second location.","Myrtle Recovery Centers is a 30-bed facility providing detox, residential, MAT, and OBOT services."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142084,"accession_number":"0001641172-25-021128","cik":1812360,"company_name":"FOXO TECHNOLOGIES INC.","ticker":"FOXO","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"FOXO Technologies implements 1-for-1.99 reverse stock split effective July 27, 2025","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1:1.99 ratio; every 1.99 pre-split shares become 1 share, par value unchanged.","Effective at 4:01 p.m. ET on July 27, 2025; post-split trading began July 28 under new CUSIP 351471503.","No fractional shares; holders of fractional interests receive rounded-up whole share.","Charter Amendment filed as Exhibit 3.1; no change to authorized share count disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142083,"accession_number":"0001641172-25-020197","cik":1812360,"company_name":"FOXO TECHNOLOGIES INC.","ticker":"FOXO","form_type":"8-K","filed_at":"2025-07-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FOXO Tech board approves spin-off of epigenetics subsidiary FOXO Labs","event_type":"other_material","confidence":"high","bullets":["Board approved pursuing spin-off of FOXO Labs, Inc., its epigenetics subsidiary; FOXO shareholders to directly own shares in the new entity.","FOXO will retain some ownership in the spun-off company while simplifying each entity's business model.","FOXO Labs owns patent for machine learning model using DNA epigenetic data; focuses on saliva-based biomarker testing for health/longevity.","Spin-off intended to create subscription-based revenue model for personal health and longevity coaching using AI and epigenetic analysis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142082,"accession_number":"0001641172-25-020090","cik":1812360,"company_name":"FOXO TECHNOLOGIES INC.","ticker":"FOXO","form_type":"8-K","filed_at":"2025-07-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FOXO Technologies approves 1-for-1.99 reverse stock split to meet NYSE American listing requirement","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio of 1:1.99; effective at 4:01pm ET on July 27, 2025.","Common stock to trade on split-adjusted basis under same symbol FOXO starting July 28, 2025.","Split designed to ensure stock price remains above NYSE American's $0.10 minimum bid requirement.","Majority shareholder approved split on June 23, 2025; fractional shares rounded up to whole shares.","All outstanding options, warrants, and convertible securities will be proportionately adjusted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160064,"accession_number":"0001641172-25-017127","cik":1812360,"company_name":"FOXO TECHNOLOGIES INC.","ticker":"FOXO","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FOXO subsidiary Myrtle Recovery approved for second year of Scott County opioid abatement funds","event_type":"regulatory","confidence":"high","bullets":["Myrtle Recovery Centers approved to receive Scott County Opioid Abatement Funds for a second year, starting July 1, 2025.","Funds will provide care for uninsured patients from Scott County at the Oneida, Tennessee facility.","Facility is operating at capacity with a waiting list, according to Myrtle CEO Robert Merritt.","Parent FOXO expects Myrtle to contribute significant revenue and value in future years through organic growth and acquisition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160063,"accession_number":"0001641172-25-016811","cik":1812360,"company_name":"FOXO TECHNOLOGIES INC.","ticker":"FOXO","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"FOXO Technologies designates Series E Preferred Stock for acquisitions","event_type":"other_material","confidence":"high","bullets":["Series E Preferred Stock: $25 stated value, 2.5% annual cash dividend paid semi-annually, plus 5.0% common stock dividend paid semi-annually.","Preferred is secured by stock of FOXO Acquisition Corp, a newly formed acquisition vehicle.","Company intends to use Series E as acquisition currency and for capital raising, non-dilutive to common shareholders.","FOXO plans to publicly list Series E Preferred Stock under its own trading symbol at the appropriate time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160062,"accession_number":"0001641172-25-016700","cik":1812360,"company_name":"FOXO TECHNOLOGIES INC.","ticker":"FOXO","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"FOXO Technologies majority stockholder approves 1:1.99 reverse split and multiple share issuances","event_type":"other_material","confidence":"high","bullets":["Majority stockholder (82.08% voting rights) approved reverse stock split at 1:1.99 ratio, effective by Nov 6, 2025.","Approved issuance of shares exceeding 20% threshold for conversions of Series A-D preferred stock, convertible notes, and exchange agreement with Smithline.","Also approved share issuances to finder J.H. Darbie & Co. and director Bret Barnes (40,000 shares) per NYSE American rules.","Actions become effective 20 days after mailing definitive Information Statement on Schedule 14C."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160061,"accession_number":"0001641172-25-015447","cik":1812360,"company_name":"FOXO TECHNOLOGIES INC.","ticker":"FOXO","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FOXO's Big South Fork Medical Center launches wound care services, aiming to boost revenues","event_type":"other_material","confidence":"high","bullets":["Big South Fork Medical Center in Oneida, TN begins inpatient and outpatient wound care.","Growing demand for wound care, especially for diabetic patients with healing complications.","CEO Seamus Lagan says expansion will increase net revenues and may lead to further offerings.","Hospital is a critical access hospital (CAH) serving rural East Tennessee.","FOXO also operates a 30-bed behavioral health facility and FOXO Labs biotech subsidiary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160060,"accession_number":"0001641172-25-015132","cik":1812360,"company_name":"FOXO TECHNOLOGIES INC.","ticker":"FOXO","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"FOXO forms acquisition subsidiary, issues preferred stock, appoints CEO as interim CFO after CFO death","event_type":"other_material","confidence":"high","bullets":["Formed FOXO Acquisition Corp., a wholly-owned subsidiary for healthcare services acquisitions; plans to create publicly listed non-convertible preferred stock for funding.","Appointed CEO Seamus Lagan as interim CFO after Martin Ward passed away on June 9, 2025; search for permanent CFO underway.","Amended exchange agreement with Smithline Family Trust II, increasing potential rights shares from 1.31M to 5.15M post-split; $384,297 debt remains.","Approximately $384,297 still owed to Smithline under Nov 2023 settlement; could require ~1.8M shares to settle at current price.","The new preferred stock is intended to be non-dilutive to common stockholders and generate cash/common stock dividends."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160059,"accession_number":"0001641172-25-013538","cik":1812360,"company_name":"FOXO TECHNOLOGIES INC.","ticker":"FOXO","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"FOXO Technologies enters agreement to issue 1,650 Series A Preferred shares for net proceeds of $1.5M","event_type":"other_material","confidence":"high","bullets":["Issuance of up to 1,650 shares of Series A Cumulative Convertible Redeemable Preferred Stock at three closings of 550 shares each.","Total gross proceeds of $1,650,000; net proceeds of $1,500,000 after $150,000 investor costs.","First closing on June 4, 2025; subsequent closings tied to effective date of registration statement.","CEO Seamus Lagan indicates funds will be used to close acquisition targets and continue revenue growth.","Company reported Q1 2025 net revenues >$3M and stockholders' equity of $9.7M vs -$17.5M at Sept 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160058,"accession_number":"0001641172-25-011549","cik":1812360,"company_name":"FOXO TECHNOLOGIES INC.","ticker":"FOXO","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FOXO subsidiary Big South Fork Medical Center to launch wound care services on June 2, 2025","event_type":"other_material","confidence":"high","bullets":["Big South Fork Medical Center in Oneida, TN will offer wound care services on inpatient and outpatient basis starting June 2, 2025.","Expansion addresses growing need, especially for diabetic patients with foot ulcers; CDC data: 38M+ diabetes patients, up to 15% experience foot ulcers.","Hospital CEO Hal Leftwich says the service builds on current volume of 600+ ER patients and ~300 outpatients monthly.","Parent CEO Seamus Lagan states expansion will increase revenues and explores further expansion in East Tennessee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}